chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Pain, Pain in extremity, Sinus congestion
Clinical narrative: DRY THROAT; DRY NASAL PASSAGES; SORE THROAT; SEVERE HEADACHE ALL OVER HEAD; SEVERE SINUS CONGESTION; BODY ACHEYNESS; ARM FELT LIKE GOT HIT WITH BASEBALL BAT/MUSCLE SORENESS; FATIGUE FOR 1 DAY/FATIGUE; This spontaneous report received from a patient concerned a 42 year old male. The patient's weight was 252 pounds, and height was 73 inches. The patient's concurrent conditions included: alcohol use, and non smoker, and other pre-existing medical conditions included: The patient had no known allergies/had no drug abuse or illicit drug usage. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, and batch number: 1820096 expiry: UNKNOWN) dose was not reported, administered on 15-JUL-2021 for prophylactic vaccination. No concomitant medications were reported. On 15-JUL-2021, the patient experienced fatigue for 1 day/fatigue. On 16-JUL-2021, the patient experienced arm felt like got hit with baseball bat/muscle soreness. On 14-NOV-2021, the patient experienced severe sinus congestion. On 14-NOV-2021, the patient experienced body acheyness. On 14-NOV-2021, the patient experienced severe headache all over head. On 15-NOV-2021, the patient experienced dry throat. On 15-NOV-2021, the patient experienced dry nasal passages. On 15-NOV-2021, the patient experienced sore throat. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from arm felt like got hit with baseball bat/muscle soreness on 18-JUL-2021, had not recovered from severe sinus congestion, severe headache all over head, body acheyness, dry throat, dry nasal passages, and sore throat, and the outcome of fatigue for 1 day/fatigue was not reported. This report was non-serious.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: dose administered past the expiry date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (dose administered past the expiry date) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Nov-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (dose administered past the expiry date). On 01-Nov-2021, EXPIRED PRODUCT ADMINISTERED (dose administered past the expiry date) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided. No treatment medication were provided.   Most recent FOLLOW-UP information incorporated above includes: On 08-Nov-2021: Follow-up received contains Significant information: Patient details updated. Product start date, expiry date were added.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Incorrect route of product administration, Polymerase chain reaction, Product administration error, Vaccination site haemorrhage
Clinical narrative: The injection site bled, then it stopped and clotted; When the Pharmacist injected the Moderna vaccine he told her he hit a blood vessel in her upper right arm; Vaccine administered via intravenous route; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE HAEMORRHAGE (The injection site bled, then it stopped and clotted), PRODUCT ADMINISTRATION ERROR (When the Pharmacist injected the Moderna vaccine he told her he hit a blood vessel in her upper right arm) and INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Vaccine administered via intravenous route) in a 23-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032F21A and 050E21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 on 27-Aug-2021. Concomitant products included ETONOGESTREL (NEXPLANON) from 02-Aug-2018 to an unknown date for Birth control.   On 07-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Nov-2021 at 10:25 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intravenous) dosage was changed to 1 dosage form. On 04-Nov-2021, the patient experienced PRODUCT ADMINISTRATION ERROR (When the Pharmacist injected the Moderna vaccine he told her he hit a blood vessel in her upper right arm) and INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Vaccine administered via intravenous route). On 04-Nov-2021 at 10:25 AM, the patient experienced VACCINATION SITE HAEMORRHAGE (The injection site bled, then it stopped and clotted). The patient was treated with Wound care (Bandaid) for Vaccination site haemorrhage. On 04-Nov-2021, PRODUCT ADMINISTRATION ERROR (When the Pharmacist injected the Moderna vaccine he told her he hit a blood vessel in her upper right arm) and INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Vaccine administered via intravenous route) had resolved. On 04-Nov-2021 at 10:35 AM, VACCINATION SITE HAEMORRHAGE (The injection site bled, then it stopped and clotted) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 27-Aug-2021, Polymerase chain reaction: positive (Positive) Positive.         Concomitant products included ETONOGESTREL (NEXPLANON) from 02-Aug-2018 to an unknown date for Birth control. No treatment mediation provided  Patient stated that pharmacist put a band-aid on the bleeding site.   Most recent FOLLOW-UP information incorporated above includes: On 11-Nov-2021: Follow up received on 11Nov2021, dose 1 details, patient initials and address updated, medical history, concomitant medication and new event of VACCINE ADMINISTRED VIA INTRAVENOUS ROUTE  were updated.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary mass, Lymphadenopathy, Mammogram, Ovarian mass, Pruritus
Clinical narrative: Itching on skin after 2nd vaccine; Existing mass in ovaries grew after 2nd vaccine; Can feel lump under right arm pit after 2nd vaccine; Swelling of the lymph nodes under the right arm after 2nd vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itching on skin after 2nd vaccine), OVARIAN MASS (Existing mass in ovaries grew after 2nd vaccine), AXILLARY MASS (Can feel lump under right arm pit after 2nd vaccine) and LYMPHADENOPATHY (Swelling of the lymph nodes under the right arm after 2nd vaccine) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 019B21A and 030A21A) for COVID-19 vaccination.     Concurrent medical conditions included Ovarian mass (She states that prior to vaccination she had a mass in her ovaries and after vaccination it grew.So they had to remove he ovaries.).   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-Apr-2021, the patient experienced PRURITUS (Itching on skin after 2nd vaccine). In 2021, the patient experienced OVARIAN MASS (Existing mass in ovaries grew after 2nd vaccine), AXILLARY MASS (Can feel lump under right arm pit after 2nd vaccine) and LYMPHADENOPATHY (Swelling of the lymph nodes under the right arm after 2nd vaccine). The patient was treated with Surgery (ovary removed) for Ovarian mass. At the time of the report, PRURITUS (Itching on skin after 2nd vaccine), OVARIAN MASS (Existing mass in ovaries grew after 2nd vaccine), AXILLARY MASS (Can feel lump under right arm pit after 2nd vaccine) and LYMPHADENOPATHY (Swelling of the lymph nodes under the right arm after 2nd vaccine) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Mammogram: dense breast tissue (normal) dense breast tissue.         No concomitant medication was given by reporter. No treatment medication was given by reporter According to case narrative the patient had breast Sonogram and result not provided.   Most recent FOLLOW-UP information incorporated above includes: On 05-Nov-2021: Significant Follow up-PQC provided On 08-Nov-2021: Non significant follow up appended
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Gave the booster shot 3 months post 2nd dose instead of the 6 months as recommended; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Gave the booster shot 3 months post 2nd dose instead of the 6 months as recommended) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Gave the booster shot 3 months post 2nd dose instead of the 6 months as recommended). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Gave the booster shot 3 months post 2nd dose instead of the 6 months as recommended) had resolved.      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported by reporter.  No treatment medications provided by the reporter.   Reporter stated patient experienced no adverse event.   Most recent FOLLOW-UP information incorporated above includes: On 11-Nov-2021: No adverse events reported by reporter On 12-Nov-2021: Patient details ( Initials, gender) were updated
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Dizziness
Clinical narrative: dizzy,room was going round and round; weak; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizzy,room was going round and round) and ASTHENIA (weak) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013F21A, 013M20A and 047A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 07-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 08-Nov-2021, the patient experienced DIZZINESS (dizzy,room was going round and round) and ASTHENIA (weak). At the time of the report, DIZZINESS (dizzy,room was going round and round) and ASTHENIA (weak) was resolving.            No Concomitant medications were reported.  No Treatment information was reported.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: A little pain in the arm the next day (after dose 1); This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (A little pain in the arm the next day (after dose 1)) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Depression, Hypertension, Urinary infection (Chronic), Cardiac disorder NOS (something for the heart) and Blood cholesterol abnormal.   On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Apr-2021, the patient experienced PAIN IN EXTREMITY (A little pain in the arm the next day (after dose 1)). At the time of the report, PAIN IN EXTREMITY (A little pain in the arm the next day (after dose 1)) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   Concomitant product includes unspecified drugs for depression, cholesterol, high blood pressure, something for the heart and chronic urine infection. No treatment medications were reported.   This case was linked to MOD-2021-378180 (Patient Link).
Age: 87.0
Sex: F
Vaccine: COVID19
Symptoms: Rhinorrhoea, Sneezing
Clinical narrative: sneezing; running nose; This spontaneous case was reported by a consumer and describes the occurrence of SNEEZING (sneezing) and RHINORRHOEA (running nose) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 16907577455) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Nov-2021, the patient experienced SNEEZING (sneezing) and RHINORRHOEA (running nose). At the time of the report, SNEEZING (sneezing) and RHINORRHOEA (running nose) outcome was unknown.            No concomitant medications were provided. No Treatment Information was provided.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Administered with an expired vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered with an expired vaccine) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Nov-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 08-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered with an expired vaccine). On 08-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Administered with an expired vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided by reporter. Treatment medications were not provided by reporter.   Most recent FOLLOW-UP information incorporated above includes: On 12-Nov-2021: Non Significant Follow up received and contains no new information
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site pruritus, Vaccination site swelling, Vaccination site warmth
Clinical narrative: hot at injection site; burning at injection site; itching at injection site; lump at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (hot at injection site), VACCINATION SITE PAIN (burning at injection site), VACCINATION SITE PRURITUS (itching at injection site) and VACCINATION SITE SWELLING (lump at injection site) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 033F21A, 024M20A and 039K20A) for COVID-19 vaccination.     Concomitant products included METOPROLOL, LEVOTHYROXINE, VITAMINS NOS, COLECALCIFEROL (VITAMIN D3), OXYMETAZOLINE HYDROCHLORIDE (CLARITIN ALLERGIC) and LORATADINE, PSEUDOEPHEDRINE HYDROCHLORIDE (BENADRYL 24 D) for an unknown indication.   On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In November 2021, the patient experienced VACCINATION SITE WARMTH (hot at injection site), VACCINATION SITE PAIN (burning at injection site), VACCINATION SITE PRURITUS (itching at injection site) and VACCINATION SITE SWELLING (lump at injection site). In November 2021, VACCINATION SITE SWELLING (lump at injection site) had resolved. At the time of the report, VACCINATION SITE WARMTH (hot at injection site), VACCINATION SITE PAIN (burning at injection site) and VACCINATION SITE PRURITUS (itching at injection site) outcome was unknown.            No concomitant medication details were reported. No treatment medication details were reported. The concomitant information included Probiotics.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: Severe and terrible joint pain; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Severe and terrible joint pain) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical history information was reported.  Concomitant products included IBUPROFEN (ADVIL [IBUPROFEN]) for an unknown indication.    On 08-Nov-2021 at 11:00 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Nov-2021, the patient experienced ARTHRALGIA (Severe and terrible joint pain). At the time of the report, ARTHRALGIA (Severe and terrible joint pain) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medication was reported by reporter.   Most recent FOLLOW-UP information incorporated above includes: On 08-Nov-2021: Follow-up received and contains No new information
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Patient stated he received a voicemail from the pharmacy stating he received the vaccine from yesterday; This spontaneous case was reported by a consumer and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient stated he received a voicemail from the pharmacy stating he received the vaccine from yesterday) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 051F21A, 012A21A and 010M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient stated he received a voicemail from the pharmacy stating he received the vaccine from yesterday). On 08-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Patient stated he received a voicemail from the pharmacy stating he received the vaccine from yesterday) had resolved.            No Concomitant medications were reported. No Treatment medications were reported.
Sex: U
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Got covid shot and died; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of DEATH (Got covid shot and died) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.  On 09-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. Death occurred on 30-Mar-2021 The patient died on 30-Mar-2021. The cause of death was not reported. It is unknown if an autopsy was performed. Not Provided   Concomitant medications were not reported.  Treatment medications were not reported.  Company Comment - This case concerns a patient of an unknown age and gender with no relevant medical history, who experienced the unexpected event of Death. The event occurred 22 days after receiving an unknown dose number of mRNA-1273 Vaccine with a fatal outcome. The rechallenge was unknown since only information about an unknown dose number was disclosed. The cause of death was not reported. It is unknown if an autopsy was performed. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This case concerns a patient of an unknown age and gender with no relevant medical history, who experienced the unexpected event of Death. The event occurred 22 days after receiving an unknown dose number of mRNA-1273 Vaccine with a fatal outcome. The rechallenge was unknown since only information about an unknown dose number was disclosed. The cause of death was not reported. It is unknown if an autopsy was performed. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Reported Cause(s) of Death: unknown cause of death
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, Product temperature excursion issue
Clinical narrative: 56 doses administered after temperature excursion; Vaccines went out of range high 3x for a total of 47 minutes and reached a high of 48.7; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (56 doses administered after temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccines went out of range high 3x for a total of 47 minutes and reached a high of 48.7) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 939902) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (56 doses administered after temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccines went out of range high 3x for a total of 47 minutes and reached a high of 48.7). At the time of the report, EXPIRED PRODUCT ADMINISTERED (56 doses administered after temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccines went out of range high 3x for a total of 47 minutes and reached a high of 48.7) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Vaccines were not punctured at the time of temperature excursion. The beyond use date (BUD) for the vaccine was on 14-Nov-2021.  Vaccine was administered on unknown date Nov-2021. Start date for the events was on unknown date  Nov-2021 and was recovered on Nov-2021.  No concomitant medications were reported No treatment medications were reported.
Age: 55.0
Sex: M
Vaccine: COVID19, FLUC4
Symptoms: Asthenia, Chills, Disorientation, Headache, Hypersomnia
Clinical narrative: took both vaccines at once. side effects were minor injection site pain (both sides), then fever, chills, body weakness, aches and pains, nausea, headache, lethargy, disorientation. I have never had side effects from a vaccine before, and the side effects may have come from combining the flu one
Age: 55.0
Sex: M
Vaccine: COVID19, FLUC4
Symptoms: Injection site pain, Lethargy, Nausea, Pain, Pyrexia
Clinical narrative: took both vaccines at once. side effects were minor injection site pain (both sides), then fever, chills, body weakness, aches and pains, nausea, headache, lethargy, disorientation. I have never had side effects from a vaccine before, and the side effects may have come from combining the flu one
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, Anticoagulant therapy, Atrial flutter, Blood culture positive, Blood glucose fluctuation
Clinical narrative: Hospitalized 11/6/2021; COVID-19 positive 11/7/2021; fully vaccinated  BRIEF OVERVIEW:   Admit Date: 11/6/2021 11:56 PM Discharge Date: 11/12/2021  3:49 PM   Hospital Course: 82-year-old male past medical history factor 5 Leiden deficiency on Eliquis, CKD stage 3, type 2 diabetes mellitus, coronary artery disease, atrial flutter, chronic obstructive pulmonary disease presents with cough and shortness of breath.  In the emergency department, electrocardiogram with atrial flutter rate controlled no acute ischemic changes.  Patient met sepsis criteria and was administered IV fluid resuscitation.  Blood cultures obtained.  Patient was started on IV antibiotics.  Chest x-ray with notable left apical pneumonia.  Labs significant for leukocytosis, lactic acidosis, mild hyperkalemia, elevated BNP, elevated procalcitonin, and COVID-19 PCR positive.  CT thorax with consolidative pneumonia as well as COVID-19.  Lactic acidosis resolved after IV fluid intervention and IV fluids were truncated.  Hospitalist service consulted for admission further evaluation.  As MRSA screen was positive, antibiotics were transitioned to oral Doxycycline and continued for 4 more days at discharge. Peripheral blood culture 1 of 2 bottles positive for staphylococci is capitis suspected to be contamination.  Sputum culture was positive for MRSA.   Patient underwent PT/OT advised home with assist home health PT/OT.  Case manager consulted for arrange for outpatient services.  SLP evaluated and patient was cleared for oral diet.   Patient had notable AKI which was minimally improved with holding of diuresis.  He was in noted to be severely hyperkalemic and was administered hyperkalemia protocol. Patient was continued on beta blocker but lisinopril was held due to hyperkalemia. Due to elevated blood pressures, patient was started on oral hydralazine to be continued at discharge with close follow up with PCP and patient needs further adjustment of medications at follow up.  Patient had fluctuating blood sugars and was resumed on home regimen of insulin at discharge. For factor V deficiency, patient was continued on Eliquis.  Patient was discharged to Home without services in stable condition.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Blood pressure increased, Brain natriuretic peptide increased, Breath sounds abnormal, COVID-19, Chest X-ray abnormal
Clinical narrative: Hospitalized 11/6/2021; COVID-19 positive 11/7/2021; fully vaccinated  BRIEF OVERVIEW:   Admit Date: 11/6/2021 11:56 PM Discharge Date: 11/12/2021  3:49 PM   Hospital Course: 82-year-old male past medical history factor 5 Leiden deficiency on Eliquis, CKD stage 3, type 2 diabetes mellitus, coronary artery disease, atrial flutter, chronic obstructive pulmonary disease presents with cough and shortness of breath.  In the emergency department, electrocardiogram with atrial flutter rate controlled no acute ischemic changes.  Patient met sepsis criteria and was administered IV fluid resuscitation.  Blood cultures obtained.  Patient was started on IV antibiotics.  Chest x-ray with notable left apical pneumonia.  Labs significant for leukocytosis, lactic acidosis, mild hyperkalemia, elevated BNP, elevated procalcitonin, and COVID-19 PCR positive.  CT thorax with consolidative pneumonia as well as COVID-19.  Lactic acidosis resolved after IV fluid intervention and IV fluids were truncated.  Hospitalist service consulted for admission further evaluation.  As MRSA screen was positive, antibiotics were transitioned to oral Doxycycline and continued for 4 more days at discharge. Peripheral blood culture 1 of 2 bottles positive for staphylococci is capitis suspected to be contamination.  Sputum culture was positive for MRSA.   Patient underwent PT/OT advised home with assist home health PT/OT.  Case manager consulted for arrange for outpatient services.  SLP evaluated and patient was cleared for oral diet.   Patient had notable AKI which was minimally improved with holding of diuresis.  He was in noted to be severely hyperkalemic and was administered hyperkalemia protocol. Patient was continued on beta blocker but lisinopril was held due to hyperkalemia. Due to elevated blood pressures, patient was started on oral hydralazine to be continued at discharge with close follow up with PCP and patient needs further adjustment of medications at follow up.  Patient had fluctuating blood sugars and was resumed on home regimen of insulin at discharge. For factor V deficiency, patient was continued on Eliquis.  Patient was discharged to Home without services in stable condition.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Computerised tomogram thorax abnormal, Condition aggravated, Coronary artery disease, Cough, Dyspnoea
Clinical narrative: Hospitalized 11/6/2021; COVID-19 positive 11/7/2021; fully vaccinated  BRIEF OVERVIEW:   Admit Date: 11/6/2021 11:56 PM Discharge Date: 11/12/2021  3:49 PM   Hospital Course: 82-year-old male past medical history factor 5 Leiden deficiency on Eliquis, CKD stage 3, type 2 diabetes mellitus, coronary artery disease, atrial flutter, chronic obstructive pulmonary disease presents with cough and shortness of breath.  In the emergency department, electrocardiogram with atrial flutter rate controlled no acute ischemic changes.  Patient met sepsis criteria and was administered IV fluid resuscitation.  Blood cultures obtained.  Patient was started on IV antibiotics.  Chest x-ray with notable left apical pneumonia.  Labs significant for leukocytosis, lactic acidosis, mild hyperkalemia, elevated BNP, elevated procalcitonin, and COVID-19 PCR positive.  CT thorax with consolidative pneumonia as well as COVID-19.  Lactic acidosis resolved after IV fluid intervention and IV fluids were truncated.  Hospitalist service consulted for admission further evaluation.  As MRSA screen was positive, antibiotics were transitioned to oral Doxycycline and continued for 4 more days at discharge. Peripheral blood culture 1 of 2 bottles positive for staphylococci is capitis suspected to be contamination.  Sputum culture was positive for MRSA.   Patient underwent PT/OT advised home with assist home health PT/OT.  Case manager consulted for arrange for outpatient services.  SLP evaluated and patient was cleared for oral diet.   Patient had notable AKI which was minimally improved with holding of diuresis.  He was in noted to be severely hyperkalemic and was administered hyperkalemia protocol. Patient was continued on beta blocker but lisinopril was held due to hyperkalemia. Due to elevated blood pressures, patient was started on oral hydralazine to be continued at discharge with close follow up with PCP and patient needs further adjustment of medications at follow up.  Patient had fluctuating blood sugars and was resumed on home regimen of insulin at discharge. For factor V deficiency, patient was continued on Eliquis.  Patient was discharged to Home without services in stable condition.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea exertional, Electrocardiogram abnormal, Essential hypertension, Factor V deficiency, Hyperkalaemia
Clinical narrative: Hospitalized 11/6/2021; COVID-19 positive 11/7/2021; fully vaccinated  BRIEF OVERVIEW:   Admit Date: 11/6/2021 11:56 PM Discharge Date: 11/12/2021  3:49 PM   Hospital Course: 82-year-old male past medical history factor 5 Leiden deficiency on Eliquis, CKD stage 3, type 2 diabetes mellitus, coronary artery disease, atrial flutter, chronic obstructive pulmonary disease presents with cough and shortness of breath.  In the emergency department, electrocardiogram with atrial flutter rate controlled no acute ischemic changes.  Patient met sepsis criteria and was administered IV fluid resuscitation.  Blood cultures obtained.  Patient was started on IV antibiotics.  Chest x-ray with notable left apical pneumonia.  Labs significant for leukocytosis, lactic acidosis, mild hyperkalemia, elevated BNP, elevated procalcitonin, and COVID-19 PCR positive.  CT thorax with consolidative pneumonia as well as COVID-19.  Lactic acidosis resolved after IV fluid intervention and IV fluids were truncated.  Hospitalist service consulted for admission further evaluation.  As MRSA screen was positive, antibiotics were transitioned to oral Doxycycline and continued for 4 more days at discharge. Peripheral blood culture 1 of 2 bottles positive for staphylococci is capitis suspected to be contamination.  Sputum culture was positive for MRSA.   Patient underwent PT/OT advised home with assist home health PT/OT.  Case manager consulted for arrange for outpatient services.  SLP evaluated and patient was cleared for oral diet.   Patient had notable AKI which was minimally improved with holding of diuresis.  He was in noted to be severely hyperkalemic and was administered hyperkalemia protocol. Patient was continued on beta blocker but lisinopril was held due to hyperkalemia. Due to elevated blood pressures, patient was started on oral hydralazine to be continued at discharge with close follow up with PCP and patient needs further adjustment of medications at follow up.  Patient had fluctuating blood sugars and was resumed on home regimen of insulin at discharge. For factor V deficiency, patient was continued on Eliquis.  Patient was discharged to Home without services in stable condition.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Laboratory test abnormal, Lactic acidosis, Leukocytosis, Oedema, Pneumonia
Clinical narrative: Hospitalized 11/6/2021; COVID-19 positive 11/7/2021; fully vaccinated  BRIEF OVERVIEW:   Admit Date: 11/6/2021 11:56 PM Discharge Date: 11/12/2021  3:49 PM   Hospital Course: 82-year-old male past medical history factor 5 Leiden deficiency on Eliquis, CKD stage 3, type 2 diabetes mellitus, coronary artery disease, atrial flutter, chronic obstructive pulmonary disease presents with cough and shortness of breath.  In the emergency department, electrocardiogram with atrial flutter rate controlled no acute ischemic changes.  Patient met sepsis criteria and was administered IV fluid resuscitation.  Blood cultures obtained.  Patient was started on IV antibiotics.  Chest x-ray with notable left apical pneumonia.  Labs significant for leukocytosis, lactic acidosis, mild hyperkalemia, elevated BNP, elevated procalcitonin, and COVID-19 PCR positive.  CT thorax with consolidative pneumonia as well as COVID-19.  Lactic acidosis resolved after IV fluid intervention and IV fluids were truncated.  Hospitalist service consulted for admission further evaluation.  As MRSA screen was positive, antibiotics were transitioned to oral Doxycycline and continued for 4 more days at discharge. Peripheral blood culture 1 of 2 bottles positive for staphylococci is capitis suspected to be contamination.  Sputum culture was positive for MRSA.   Patient underwent PT/OT advised home with assist home health PT/OT.  Case manager consulted for arrange for outpatient services.  SLP evaluated and patient was cleared for oral diet.   Patient had notable AKI which was minimally improved with holding of diuresis.  He was in noted to be severely hyperkalemic and was administered hyperkalemia protocol. Patient was continued on beta blocker but lisinopril was held due to hyperkalemia. Due to elevated blood pressures, patient was started on oral hydralazine to be continued at discharge with close follow up with PCP and patient needs further adjustment of medications at follow up.  Patient had fluctuating blood sugars and was resumed on home regimen of insulin at discharge. For factor V deficiency, patient was continued on Eliquis.  Patient was discharged to Home without services in stable condition.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Polyuria, Procalcitonin increased, Resuscitation, SARS-CoV-2 test positive, Sepsis
Clinical narrative: Hospitalized 11/6/2021; COVID-19 positive 11/7/2021; fully vaccinated  BRIEF OVERVIEW:   Admit Date: 11/6/2021 11:56 PM Discharge Date: 11/12/2021  3:49 PM   Hospital Course: 82-year-old male past medical history factor 5 Leiden deficiency on Eliquis, CKD stage 3, type 2 diabetes mellitus, coronary artery disease, atrial flutter, chronic obstructive pulmonary disease presents with cough and shortness of breath.  In the emergency department, electrocardiogram with atrial flutter rate controlled no acute ischemic changes.  Patient met sepsis criteria and was administered IV fluid resuscitation.  Blood cultures obtained.  Patient was started on IV antibiotics.  Chest x-ray with notable left apical pneumonia.  Labs significant for leukocytosis, lactic acidosis, mild hyperkalemia, elevated BNP, elevated procalcitonin, and COVID-19 PCR positive.  CT thorax with consolidative pneumonia as well as COVID-19.  Lactic acidosis resolved after IV fluid intervention and IV fluids were truncated.  Hospitalist service consulted for admission further evaluation.  As MRSA screen was positive, antibiotics were transitioned to oral Doxycycline and continued for 4 more days at discharge. Peripheral blood culture 1 of 2 bottles positive for staphylococci is capitis suspected to be contamination.  Sputum culture was positive for MRSA.   Patient underwent PT/OT advised home with assist home health PT/OT.  Case manager consulted for arrange for outpatient services.  SLP evaluated and patient was cleared for oral diet.   Patient had notable AKI which was minimally improved with holding of diuresis.  He was in noted to be severely hyperkalemic and was administered hyperkalemia protocol. Patient was continued on beta blocker but lisinopril was held due to hyperkalemia. Due to elevated blood pressures, patient was started on oral hydralazine to be continued at discharge with close follow up with PCP and patient needs further adjustment of medications at follow up.  Patient had fluctuating blood sugars and was resumed on home regimen of insulin at discharge. For factor V deficiency, patient was continued on Eliquis.  Patient was discharged to Home without services in stable condition.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Sputum culture positive, Staphylococcus test positive
Clinical narrative: Hospitalized 11/6/2021; COVID-19 positive 11/7/2021; fully vaccinated  BRIEF OVERVIEW:   Admit Date: 11/6/2021 11:56 PM Discharge Date: 11/12/2021  3:49 PM   Hospital Course: 82-year-old male past medical history factor 5 Leiden deficiency on Eliquis, CKD stage 3, type 2 diabetes mellitus, coronary artery disease, atrial flutter, chronic obstructive pulmonary disease presents with cough and shortness of breath.  In the emergency department, electrocardiogram with atrial flutter rate controlled no acute ischemic changes.  Patient met sepsis criteria and was administered IV fluid resuscitation.  Blood cultures obtained.  Patient was started on IV antibiotics.  Chest x-ray with notable left apical pneumonia.  Labs significant for leukocytosis, lactic acidosis, mild hyperkalemia, elevated BNP, elevated procalcitonin, and COVID-19 PCR positive.  CT thorax with consolidative pneumonia as well as COVID-19.  Lactic acidosis resolved after IV fluid intervention and IV fluids were truncated.  Hospitalist service consulted for admission further evaluation.  As MRSA screen was positive, antibiotics were transitioned to oral Doxycycline and continued for 4 more days at discharge. Peripheral blood culture 1 of 2 bottles positive for staphylococci is capitis suspected to be contamination.  Sputum culture was positive for MRSA.   Patient underwent PT/OT advised home with assist home health PT/OT.  Case manager consulted for arrange for outpatient services.  SLP evaluated and patient was cleared for oral diet.   Patient had notable AKI which was minimally improved with holding of diuresis.  He was in noted to be severely hyperkalemic and was administered hyperkalemia protocol. Patient was continued on beta blocker but lisinopril was held due to hyperkalemia. Due to elevated blood pressures, patient was started on oral hydralazine to be continued at discharge with close follow up with PCP and patient needs further adjustment of medications at follow up.  Patient had fluctuating blood sugars and was resumed on home regimen of insulin at discharge. For factor V deficiency, patient was continued on Eliquis.  Patient was discharged to Home without services in stable condition.
Age: 44.0
Sex: M
Vaccine: COVID19
Symptoms: Injection site swelling
Clinical narrative: Site: Swelling at Injection Site-Medium.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Injection site erythema, Injection site pain, Injection site pruritus
Clinical narrative: Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Systemic: Allergic: Itch (specify: facial area, extremeties)-Medium, Systemic: Allergic: Rash (specify: facial area, extremeties)-Medium, Systemic: Body Aches Generalized-Mild, Systemic: Exhaustion / Lethargy-Mild, Systemic: Fever-Mild, Systemic: Headache-Medium, Systemic: Nausea-Medium, Additional Details: Flu and COVID vaccine were given in the same arm the same day.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site swelling, Lethargy, Nausea, Pain, Pruritus
Clinical narrative: Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Systemic: Allergic: Itch (specify: facial area, extremeties)-Medium, Systemic: Allergic: Rash (specify: facial area, extremeties)-Medium, Systemic: Body Aches Generalized-Mild, Systemic: Exhaustion / Lethargy-Mild, Systemic: Fever-Mild, Systemic: Headache-Medium, Systemic: Nausea-Medium, Additional Details: Flu and COVID vaccine were given in the same arm the same day.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Rash
Clinical narrative: Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Systemic: Allergic: Itch (specify: facial area, extremeties)-Medium, Systemic: Allergic: Rash (specify: facial area, extremeties)-Medium, Systemic: Body Aches Generalized-Mild, Systemic: Exhaustion / Lethargy-Mild, Systemic: Fever-Mild, Systemic: Headache-Medium, Systemic: Nausea-Medium, Additional Details: Flu and COVID vaccine were given in the same arm the same day.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Incorrect dose administered
Clinical narrative: Error: Wrong Dose of Vaccine - Too Low-
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Fatigue, Lethargy, Pain, Syncope
Clinical narrative: Systemic: Abdominal Pain-Mild, Systemic: Body Aches Generalized-Mild, Systemic: Exhaustion / Lethargy-Mild, Systemic: Fainting / Unresponsive-Mild.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Unresponsive to stimuli
Clinical narrative: Systemic: Abdominal Pain-Mild, Systemic: Body Aches Generalized-Mild, Systemic: Exhaustion / Lethargy-Mild, Systemic: Fainting / Unresponsive-Mild.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Anion gap normal, Asthenia, Basophil count decreased, Basophil percentage decreased, Blood bicarbonate normal
Clinical narrative: Patient is a 72 y.o. male who presented to emergency department with complaints of generalized weakness.  He has a past medical history of Alzheimer's dementia- end stage, chronic obstructive pulmonary disease, mutation of bilateral arms below the elbow, and prosthetic left eye. Patient presented with complaints of generalized weakness.  At baseline, he does have dementia which limits assessment ability.  Per his daughter, he has had multiple falls recently.  She states that he ambulates independently, however, very slowly.  Upon examination, patient has no specific complaints.  Patient's daughter has concerns that his wife, who is his primary caregiver is unable to care for the patient because she herself has COVID-19.  In the emergency department, patient's vital signs were stable.  He did not require supplemental oxygen.  Complete blood count and BMP were unremarkable.  COVID-19 was positive.  EKG shows normal sinus rhythm.  CT scan of the head showed chronic maxillary sinusitis and chronic generalized brain atrophy.  CT of the chest showed no acute abnormalities.  Suspect generalized weakness secondary to COVID-19.  Patient has been transferred and admitted to Hospital further evaluation management of generalized weakness.   Patient was evaluated and qualified for monoclonal antibodies. Patient's daughter was at bedside and reported ability to care for patient 24/7 until spouse was able to continue normal care. Risk and benefits discussed with daughter who agreed upon infusion and discharge home when safe. Patient received therapy without interactions.    The patient was evaluated by PT and OT, both therapists recommended subacute rehab and a walker for home use. This was discussed with the patient and daughter; the daughter plans to bring him to her home with 24 hour care until his wife (primary caregiver) is recovered from COVID infection.  The patient continues on room air, he has some fatigue, but is otherwise stable.  The patient will be discharged in the care of his daughter until he can return home.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Blood calcium normal, Blood chloride normal, Blood creatinine normal, Blood glucose normal, Blood potassium normal
Clinical narrative: Patient is a 72 y.o. male who presented to emergency department with complaints of generalized weakness.  He has a past medical history of Alzheimer's dementia- end stage, chronic obstructive pulmonary disease, mutation of bilateral arms below the elbow, and prosthetic left eye. Patient presented with complaints of generalized weakness.  At baseline, he does have dementia which limits assessment ability.  Per his daughter, he has had multiple falls recently.  She states that he ambulates independently, however, very slowly.  Upon examination, patient has no specific complaints.  Patient's daughter has concerns that his wife, who is his primary caregiver is unable to care for the patient because she herself has COVID-19.  In the emergency department, patient's vital signs were stable.  He did not require supplemental oxygen.  Complete blood count and BMP were unremarkable.  COVID-19 was positive.  EKG shows normal sinus rhythm.  CT scan of the head showed chronic maxillary sinusitis and chronic generalized brain atrophy.  CT of the chest showed no acute abnormalities.  Suspect generalized weakness secondary to COVID-19.  Patient has been transferred and admitted to Hospital further evaluation management of generalized weakness.   Patient was evaluated and qualified for monoclonal antibodies. Patient's daughter was at bedside and reported ability to care for patient 24/7 until spouse was able to continue normal care. Risk and benefits discussed with daughter who agreed upon infusion and discharge home when safe. Patient received therapy without interactions.    The patient was evaluated by PT and OT, both therapists recommended subacute rehab and a walker for home use. This was discussed with the patient and daughter; the daughter plans to bring him to her home with 24 hour care until his wife (primary caregiver) is recovered from COVID infection.  The patient continues on room air, he has some fatigue, but is otherwise stable.  The patient will be discharged in the care of his daughter until he can return home.